DMD Therapeutics
Facts
- HQ
- Seattle, WA, US
- Sectors
- Biotech, Life Sciences
- Founded
- 2017
- Stage
- Seed
Is this your organization? Claim it
UW spinout DMD Therapeutics raises $400,000 from three foundations to advance DMD-813 toward human trials
DMD Therapeutics, a University of Washington spinout led by Ron Berenson, raised $400,000 from three DMD-focused foundations to advance its lead candidate DMD-813 — which showed positive results in mouse studies — toward human trials and early manufacturing.
Seattle Serial Entrepreneur Ron Berenson’s New UW Spin‑Off DMD Therapeutics Files to Raise $600,000
Ron Berenson has launched a new Seattle biotech startup, DMD Therapeutics, which filed to raise $600,000 with Berenson listed as president; the company is a University of Washington spin-off currently operating in stealth mode. Berenson is a serial entrepreneur who leads several other biotech and medical companies and has a long history in Seattle’s biotech scene.